Genmab — November 2015
-
Sydbanks kommentarer til regnskabet på analysesiden: http://www.proinvestor.com/analyser
-
Carnegie opjuster FING med 51%.
-
-
-
Selv om det nye abstract for Dara/Len/Dex havde data cut i januar, så er forbedringen fra ASH 14 fin. Fra 7 %CR, 43% VGPR og 37% PR til nu (foreløbig) 25% CR /de fleste sCR), 28% VGPR og 34 % PR. Plus 93% stadig i behandling. Selv om det vel var ventet med udviklingen i CR, så alligevel særdeles godt. Spændende om det bliver bedre endnu, når der kommer data fra ekstra 6 måneders behandlingstid.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind